SUMMIT: Tirzepatide and heart failure with preserved ejection fraction SUMMIT (Packer et al., NEJM 2024, NEJMoa2410027, PMID 39555826) randomized 731 patients with heart failure with preserved ejection fraction (HFpEF) and a BMI 30 to tirzepatide up to 15 mg/week or placebo, with a median follow-up of 104 weeks
This positions FOXO4-DRI within advanced molecular longevity research rather than endocrine or metabolic peptide categories
The most comprehensive study, published in BioMed Research International (2021), found that 5-amino-1MQ treatment "reverses diet-induced obesity and related T2D" in obese mice
The microbiome-gut-brain content axis consists of three bidirectional, biochemical, signaling pathways between the gut and the brain, and these three pathways include the nervous, endocrine, and immune pathways (198)